ReviewHuman molecular genetics2011
Ex vivo gene therapy for HIV-1 treatment.
Review in Human molecular genetics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity.Nature biotechnology · 2016Article
- A Conserved Target Site in HIV-1 Gag RNA is Accessible to Inhibition by Both an HDV Ribozyme and a Short Hairpin RNA.Molecular therapy. Nucleic acids · 2014Article
- A quantitative comparison of anti-HIV gene therapy delivered to hematopoietic stem cells versus CD4+ T cells.PLoS computational biology · 2014Article
- Identification of Hematopoietic Stem Cell Engraftment Genes in Gene Therapy Studies.Journal of stem cell research & therapy · 2013Article
- HIV/AIDS eradication.Bioorganic & medicinal chemistry letters · 2013Review
- Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAART.Gene therapy · 2013Review
- Hematopoietic cell transplantation with cord blood for cure of HIV infections.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2013Article
- Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized mice.PLoS pathogens · 2013Article
- Creating genetic resistance to HIV.Current opinion in immunology · 2012Review
- Controversies in HIV cure research.Journal of the International AIDS Society · 2012Article
- Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice.PloS one · 2012Article
- Recombinant interferon-γ lentivirus co-infection inhibits adenovirus replication ex vivo.PloS one · 2012Article
- A SELEX-screened aptamer of human hepatitis B virus RNA encapsidation signal suppresses viral replication.PloS one · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Until recently, progress in ex vivo gene therapy (GT) for human immunodeficiency virus-1 (HIV-1) treatment has been incremental. Long-term HIV-1 remission in a patient who received a heterologous stem cell transplant for acquired immunodeficiency syndrome-related lymphoma from a CCR5(-/-) donor, even after discontinuation of conventional therapy, has energized the field. We review the status of current approaches as well as future directions in the areas of therapeutic targets, combinatorial strategies, vector design, introduction of therapeutics into stem cells and enrichment/expansion of gene-modified cells. Finally, we discuss recent advances towards clinical application of HIV-1 GT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.